These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32521616)

  • 41. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatic steatosis after switching to integrase inhibitor-based regimens does not parallel short-term weight gain.
    Gonzalez-Serna A; Macías J; Rincon P; Arriaza MJ; Corma-Gomez A; Santos M; Fernandez-Fuertes M; Pineda JA; Real LM
    AIDS; 2023 Nov; 37(14):2259-2262. PubMed ID: 37877283
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in HIV-1 Infected Turkish Patients.
    Sayan M; Gündüz A; Ersöz G; İnan A; Deveci A; Özgür G; Sargın F; Karagöz G; İnci A; İnan D; Ülçay A; Karaoğlan I; Kaya S; Kutlu SS; Süer K; Çağatay A; Akalın H
    HIV Clin Trials; 2016 May; 17(3):109-13. PubMed ID: 27125365
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Virological response to integrase strand transfer inhibitor-based antiretroviral combinations in HIV-1 group O-infected patients.
    Alessandri-Gradt E; Unal G; Leoz M; Plantier JC;
    AIDS; 2019 Jul; 33(8):1327-1333. PubMed ID: 30950879
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to an Integrase Strand Transfer Inhibitor-Containing Regimen: Results from an Observational Cohort Study.
    Merlini E; Cazzaniga FA; Casabianca A; Orlandi C; Magnani M; Ancona G; Tincati C; d'Arminio Monforte A; Marchetti G
    Clin Drug Investig; 2019 Dec; 39(12):1239-1249. PubMed ID: 31531832
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan.
    Chang SY; Lin PH; Cheng CL; Chen MY; Sun HY; Hsieh SM; Sheng WH; Su YC; Su LH; Chang SF; Liu WC; Hung CC; Chang SC
    Sci Rep; 2016 Oct; 6():35779. PubMed ID: 27779200
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting.
    Greenberg L; Ryom L; Neesgaard B; Miró JM; Dahlerup Rasmussen L; Zangerle R; Grabmeier-Pfistershammer K; Günthard HF; Kusejko K; Smith C; Mussini C; Menozzi M; Wit F; Van Der Valk M; d'Arminio Monforte A; De Wit S; Necsoi C; Pelchen-Matthews A; Lundgren J; Peters L; Castagna A; Muccini C; Vehreschild JJ; Pradier C; Bruguera Riera A; Sönnerborg A; Petoumenos K; Garges H; Rogatto F; Dedes N; Bansi-Matharu L; Mocroft A;
    Open Forum Infect Dis; 2022 Mar; 9(3):ofac029. PubMed ID: 35198646
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results.
    Oldenbuettel C; Wolf E; Ritter A; Noe S; Heldwein S; Pascucci R; Wiese C; Von Krosigk A; Jaegel-Guedes E; Jaeger H; Balogh A; Koegl C; Spinner CD
    Antivir Ther; 2017; 22(2):169-172. PubMed ID: 27588613
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
    Hachiya A; Ode H; Matsuda M; Kito Y; Shigemi U; Matsuoka K; Imamura J; Yokomaku Y; Iwatani Y; Sugiura W
    Antiviral Res; 2015 Jul; 119():84-8. PubMed ID: 25956162
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing.
    Nguyen T; Fofana DB; Lê MP; Charpentier C; Peytavin G; Wirden M; Lambert-Niclot S; Desire N; Grude M; Morand-Joubert L; Flandre P; Katlama C; Descamps D; Calvez V; Todesco E; Marcelin AG
    J Antimicrob Chemother; 2018 Sep; 73(9):2485-2492. PubMed ID: 29873733
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HIV-1 integrase strand-transfer inhibitor resistance in southern Taiwan.
    Tsai HC; Chen IT; Wu KS; Tseng YT; Sy CL; Chen JK; Lee SS; Chen YS
    Oncotarget; 2018 May; 9(38):24927-24935. PubMed ID: 29861843
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus.
    Kileel EM; Lo J; Malvestutto C; Fitch KV; Zanni MV; Fichtenbaum CJ; Overton ET; Okeke NL; Kumar P; Joao E; Aberg JA; Martinez E; Currier JS; Douglas PS; Ribaudo HJ; Grinspoon SK
    Open Forum Infect Dis; 2021 Dec; 8(12):ofab537. PubMed ID: 34888395
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Single-Center Retrospective Cohort Analysis of Maternal and Infant Outcomes in HIV-Infected Mothers Treated with Integrase Inhibitors During Pregnancy.
    Mounce ML; Pontiggia L; Adams JL
    Infect Dis Ther; 2017 Dec; 6(4):531-544. PubMed ID: 28905222
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment outcomes in perinatally infected HIV-positive adolescents and young adults after ≥10 years on antiretroviral therapy.
    Anderson K; Muloiwa R; Davies MA
    S Afr Med J; 2018 Dec; 109(1):27-34. PubMed ID: 30606301
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of pretreatment variables on plasma HIV RNA value at the sixth month of antiretroviral therapy including all first line drugs in HIV naïve patients: A path analysis approach.
    Mengoli C; Basso M; Andreis S; Scaggiante R; Cruciani M; Ferretto R; Panese S; Manfrin V; Francisci D; Schiaroli E; Maffongelli G; Sarmati L; Andreoni M; Baldelli F; Palu' G; Parisi SG
    PLoS One; 2019; 14(3):e0213160. PubMed ID: 30856186
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection.
    Ambrosioni J; Nicolás D; Manzardo C; Agüero F; Blanco JL; Mosquera MM; Peñafiel J; Gatell JM; Marcos MA; Miró JM
    J Antimicrob Chemother; 2017 Jan; 72(1):205-209. PubMed ID: 27624569
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resistance-Associated Mutations and Polymorphisms among Integrase Inhibitor-Naïve HIV-1 Patients in Kuwait.
    Chehadeh W; Albaksami O; John SE; Al-Nakib W
    Intervirology; 2017; 60(4):131-137. PubMed ID: 29212076
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO.
    Mboumba Bouassa RS; Mossoro-Kpinde CD; Gody JC; Veyer D; Péré H; Matta M; Robin L; Grésenguet G; Charpentier C; Bélec L
    J Antimicrob Chemother; 2019 Jul; 74(7):2030-2038. PubMed ID: 30891603
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
    Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
    Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France.
    Pugliese P; Joly V; Valantin MA; Cotte L; Huleux T; Allavena C; Reynes J; Poizot-Martin I; Bani-Sadr F; Cuzin L;
    Med Mal Infect; 2019 Jun; 49(4):264-269. PubMed ID: 30409541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.